GlassScriptPhysician profile
Naomitsu Watanabe
NPI 1821542895
$4,163.64
in general payments reported to CMS, 2019-2025
29 companies · $56.09 in 2025
The $56.09 reported for 2025 was less than what a typical Internal Medicine provider received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $339 · 2022: $581 · 2023: $1,732 · 2024: $1,456 · 2025: $56.09.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,244.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,243.92 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Glaxosmithkline, LLC. | $952.18 | 2022-2024 | Trelegy Ellipta, Arexvy, Shingrix |
| Astrazeneca Pharmaceuticals LP | $652.44 | 2021-2024 | Farxiga, Breztri, Tezspire |
| Novo Nordisk INC | $394.01 | 2021-2024 | Ozempic, Rybelsus, Wegovy |
| Lilly USA, LLC | $183.90 | 2022-2024 | Mounjaro, Zepbound, Trulicity |
| Bayer Healthcare Pharmaceuticals INC. | $174.55 | 2021-2024 | |
| Abbvie INC. | $156.67 | 2021-2023 | Qulipta |
| Sumitomo Pharma America, INC. | $150.51 | 2023 | Gemtesa |
| Boehringer Ingelheim Pharmaceuticals, INC. | $144.15 | 2023-2024 | Jardiance |
| Amgen INC. | $136.51 | 2024-2025 | Otezla, Repatha, Otezla |
| Lundbeck LLC | $126.36 | 2021-2022 | |
| Corcept Therapeutics | $114.06 | 2023-2024 | Korlym |
| Xeris Pharmaceuticals, INC. | $113.37 | 2023 | Gvoke Hypopen |
| Horizon Therapeutics Plc | $109.99 | 2023 | Krystexxa |
| Abbott Laboratories | $100.29 | 2021-2024 | Freestyle Libre 3 |
| Dexcom, INC. | $81.14 | 2023-2024 | Dexcom G6 Transmitter |
Show all 29 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Merck Sharp & Dohme LLC | $78.02 | 2024 | Gardasil 9, Gardasil, Capvaxive |
| Pfizer INC. | $74.60 | 2022-2024 | |
| Exact Sciences Corporation | $52.43 | 2023 | Cologuard Collection Kit |
| Biohaven Pharmaceuticals, INC. | $42.98 | 2021 | |
| Neurocrine Biosciences, INC. | $41.52 | 2024 | Ingrezza |
| Embecta Corp. | $41.48 | 2023 | Bd Nano 2nd Gen Pen Needle |
| Seqirus USA INC | $41.47 | 2022-2024 | Flucelvax, Fluad |
| Sunovion Pharmaceuticals INC. | $39.04 | 2021-2022 | |
| Sanofi-Aventis U.S. LLC | $36.49 | 2021-2023 | |
| Biohaven Pharmaceutical Holding Company LTD. | $35.92 | 2022 | |
| Becton, Dickinson and Company | $28.60 | 2022 | |
| Emd Serono, INC. | $24.42 | 2025 | |
| Hikma Pharmaceuticals USA | $18.27 | 2021 | |
| Eyevance Pharmaceuticals LLC | $18.27 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Naomitsu Watanabe listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.